[Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension].
OBJECTIVE
To compare the cost-effectiveness of two anti-hypertensive therapy regimens, Compound anti-hypertensive tablets and other common anti-hypertensive agents, in the treatment program of Primary Hypertension.


METHODS
We conducted a cost-effectiveness analysis based on a community trial. Two communities' primary hypertensive patients were enrolled to receive different therapy drugs: Compound anti-hypertensive tablets (Group A) or other common anti-hypertensive agents (Group B). Blood pressure, medicine used, and adverse drug reactions were observed and recorded for one year, and then cost-effectiveness ratio of the two groups and incremental ratio were calculated. We considered a 30% drug price fluctuating load to make the sensitivity analysis.


RESULTS
2505 cases were enrolled with 1529 cases in group A and 976 cases in group B. The cost-effectiveness ratios were 418.1 and 1057.7 for Group A and B respectively while the incremental cost-effectiveness of Group B vs. Group A was 19 202.2. The results were insensitive to variation in the costs of drugs over clinically reasonable ranges.


CONCLUSIONS
Compound anti-hypertensive tablets appeared to be relatively cost-effective when compared to common drugs for the treatment of primary hypertension.
Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing 100083, China.
Yi-Qun
YQ
Wu
Yong-Hua
YH
Hu
Tao
T
Ren
Tao
T
Wu
Qiu-Shan
QS
Tao
Xue-Ying
XY
Qin
Yi
Y
Zhang
Si-Yan
SY
Zhan
Wei-Hua
WH
Cao
Li-Ming
LM
Li
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D013607:Tablets / Q000627:therapeutic use; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D013607:Tablets